NHS expenditure

In terms of curtailing NHS expenditure on medicines the effectiveness of the PPRS is more difficult to assess it has the power to restrict price increases and claw back excess profits, and the opportunities for the DoH to enforce these powers has been increased in the 1999 revision of the PPRS. The amount of money clawed back from companies each year has been insignificant in the past compared to the overall medicines expenditure, but this will change. 

---